Fisher-Hoch Susan P
Division of Epidemiology, Human Genetics and Environmental Science, University of Texas School of Public Health, Brownsville Campus, Brownsville, TX, USA.
Res Rep Trop Med. 2014 Jul 3;5:35-44. doi: 10.2147/RRTM.S45082. eCollection 2014.
Diabetes presents a greater threat to global tuberculosis (TB) control than previously appreciated, with risk of reversing the achievements of several decades. An estimated 382 million people worldwide currently have diabetes, half of whom are undiagnosed. Most live in low- and middle-income countries alongside many of the two billion individuals infected with TB. Though the frequency of TB in type 1 diabetes was known for centuries, only recently have we observed the tripling of TB in type 2 diabetes, most significantly in high-burden TB populations such as in Peru, Russia, and the People's Republic of China. In India diabetes is estimated to have increased TB cases by 46% between 1998 and 2008. Diabetes is a greater long-term threat to TB control than human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) since ten-fold more people are affected by diabetes than HIV/AIDS in larger geographic areas. Diabetes in TB increases drug resistance, treatment failure, and mortality, and may increase the spread of drug-resistant strains. Delayed or missed diagnosis fuels transmission of TB and hinders control of diabetes. Tailored treatment for diabetes patients requires well-designed clinical trials. The World Health Organization (WHO) framework for care and control of diabetes and TB needs improved screening strategies. Determination of how best to establish bi-directional screening is hampered by lack of affordable and reliable methods. Recommendations include education of health care providers, patients, and communities. Structured diabetes programs with registries and effective follow-up could be modeled on and communicate with existing TB programs. Vital research should address new diagnostic tools, lowering cost and evaluation of intervention strategies, as well as better understanding of the impaired immune responses that make diabetes patients more susceptible to TB leading to targeted therapies. Solutions will require the combination of good science, good decision-making, adequate funding, and political will.
糖尿病对全球结核病控制构成的威胁比此前认为的更大,有可能使数十年来取得的成果付诸东流。据估计,目前全球有3.82亿人患有糖尿病,其中一半未被诊断出来。大多数患者生活在低收入和中等收入国家,与20亿结核病感染者中的许多人生活在一起。虽然1型糖尿病患者中结核病的发病率几个世纪以来为人所知,但直到最近我们才发现2型糖尿病患者中结核病发病率增至三倍,在秘鲁、俄罗斯和中国等高结核病负担人群中最为显著。据估计,在印度,1998年至2008年间糖尿病使结核病病例增加了46%。糖尿病对结核病控制构成的长期威胁比人类免疫缺陷病毒(HIV)/获得性免疫缺陷综合征(AIDS)更大,因为在更大的地理区域内,受糖尿病影响的人数是受HIV/AIDS影响人数的十倍。结核病患者患糖尿病会增加耐药性、治疗失败率和死亡率,并可能增加耐药菌株的传播。诊断延迟或漏诊会助长结核病传播并阻碍糖尿病控制。为糖尿病患者量身定制治疗方案需要精心设计的临床试验。世界卫生组织(WHO)关于糖尿病和结核病护理与控制的框架需要改进筛查策略。由于缺乏经济实惠且可靠的方法,确定如何最好地开展双向筛查受到阻碍。建议包括对医疗保健提供者、患者和社区进行教育。可以仿照现有的结核病项目并与之交流互动,建立有登记制度和有效随访措施的结构化糖尿病项目。重要的研究应致力于开发新的诊断工具、降低成本并评估干预策略,以及更好地了解导致糖尿病患者更易感染结核病的免疫反应受损情况,从而实现靶向治疗。解决办法需要将优秀的科学、良好的决策、充足的资金和政治意愿结合起来。